首页|靶向药在瘢痕疙瘩治疗中的研究进展及应用前景

靶向药在瘢痕疙瘩治疗中的研究进展及应用前景

扫码查看
瘢痕疙瘩(KD)是皮肤在创伤修复过程中成纤维细胞过度增殖和细胞外基质过量沉积所形成的一种病理性瘢痕,影响外观的同时常伴有瘙痒和疼痛,严重影响患者的生活质量.治疗方法多种多样,如注射、激光和手术等,但效果并不理想.目前,尝试用于治疗瘢痕疙瘩的靶向药包括大分子单克隆抗体度普利尤单抗(Dupilumab),小分子靶向药物尼达尼布(Nintedanib)、舒尼替尼(Sunitinib)和索拉非尼(Sorafenib)等,这些靶向药的使用为未来瘢痕疙瘩的防治提供新思路新方法.本文综述以上靶向药在瘢痕疙瘩治疗中的研究进展,并展望其应用前景.
Research progress on targeted drugs and its applications in the treatment of keloids
Keloid(KD)is a pathological scar caused by excessive proliferation of fibroblasts and excessive deposition of extracellular matrix(ECM)in the skin during wound repair.It is often complicated with pain and pruritus,which can seriously affect the quality of life of patients.Al-though various treatments,such as injections,lasers,and surgeries,are available,the outcome is not satisfactory.Therefore,targeted therapeutic regimens,including a large molecule monoclonal antibody(Dupilumab)and the small molecule targeted drugs(Nintedanib,Sorafenib and Sunitinib),have been deployed to treat keloids.This review summarizes the progress on the treat-ment of keloids with these targeted drugs and their applications in the future.

keloidtargeted drugDupliumabNintedanibSunitinibSorafenib

高俊智、罗银利、皮龙泉、金哲虎

展开 >

延边大学附属医院,吉林 延吉 133000

瘢痕疙瘩 靶向药物 度普利尤单抗 尼达尼布 舒尼替尼 索拉非尼

国家自然科学基金

81960561

2024

皮肤性病诊疗学杂志
广东省皮肤性病防治中心

皮肤性病诊疗学杂志

影响因子:0.666
ISSN:1674-8468
年,卷(期):2024.31(1)
  • 1